A once-weekly injectable glucose-dependent insulinotropic polypeptide/GLP-1 dual agonist conferred up to 14.7% weight loss at ...
News Medical on MSN
New role for GLP-1 drugs: Improving survival in people with severe psychiatric disorders
By Tarun Sai Lomte An expert editorial suggests that widely used diabetes and obesity drugs may help close the long-standing ...
Experts say that improving heart and metabolic health may be key to helping people with severe mental illness live longer, ...
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline results from CT388-103, a Phase II clinical trial of CT-388, an investigational dual GLP-1/GIP ...
Bariatric surgery and GLP-1 drugs are associated with reductions in fat mass and a shift in body composition toward a higher ...
This randomized controlled trial shows that structured moderate-to-vigorous exercise, alone or combined with liraglutide, ...
Gene therapy for weight loss is being explored as a potential game-changer, with therapy aiming to program the body to ...
Glucagon-like peptide-1 receptor agonist drugs (commonly referred to as GLP-1 agonists) have become widely prescribed for ...
New research reveals these medications impact everything from heart health to restaurant menus.
Welcome to The Thin Line, The New York Post’s new series about the darker side of GLP-1 drugs. Though GLP-1 agonists sold ...
HealthDay News — Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with a reduced risk for colorectal ...
A once-weekly subcutaneous injection of CT-388 achieved a statistically significant placebo-adjusted weight loss of 22.5% (p ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results